INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/04/2026
Voltar para busca
Dado oficial do USPTO
VACSAF
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
02/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
27/10/2017
Data de registro
15/01/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/08/2025
Última transação
02/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Belfast Co. Antrim BT3 9DT, GB
Examinador
MAYER, DAVID COREY
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SISAF Ltd
Representantes
Helen Hill Minsker Banner & Witcoff, Ltd.
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals and chemical preparations for use in industryscience and research; Biochemical substances and biochemical preparations for use in industryscience and researchexcipients for use in the manufacture of pharmaceutical preparationscosmetic preparationsnutraceutical preparationsveterinary preparationsdietary supplementsfoods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceuticalmedical and veterinary research in the nature of reagents and substrateschemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industryscience and research; Silicon nanoparticle materialssilicon and silicon-based chemical compounds for use in industryscience and research; Porous silicon nanoparticle materialssilicon and silicon-based chemical compounds for use in industryscience and research; Chemical materialschemical catalysts for carrying and delivery of chemicalbiochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Nanoparticle materialssilicon-based chemical compounds for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemicalbiochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparationsreagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparationsreagents and catalysts for scientific research in the field of medicineveterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical productsincluding for the manufacture of vaccines and veterinary preparations
Classe 5
Antiviral pharmaceutical preparationsanti-infective pharmaceutical preparationsanti-inflammatory pharmaceutical preparationsantiseptic pharmaceutical preparationsantibacterial pharmaceutical preparationsantibiotic pharmaceutical preparationsantifungal pharmaceutical preparationsanti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disordersmusculoskeletal diseases and disordersinflammatory diseases and disordersrespiratory diseases and disorderspulmonary diseases and disordersimmune system related diseases and disordershematological diseases and disordersoncological diseases and disordersurological diseases and disordersgastro-intestinal diseaseseye diseases and conditionsheart rhythm disorderskidney diseasesnephropathic diseaseshematological disordersdiabeteshypertensionskin disordersdamaged skin and tissuewrinkleswounds and allergiesinsect bitesdermatological diseases and disordersHIVcancer and tumorsbone diseasesarthritiscardiopulmonary diseases and disordersinfectious diseasesblood disorderspainsepsisalopeciaobesitycognitive disorders and diseasesneurological disordershormonal disordersdisorders of the autoimmune systemmetabolic system diseases and disordersendocrine system diseases and disordersgenitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticalsnutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; Chemicalbiochemicalbiological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
C71T
CANCELLED SECTION 71
01/08/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
15/01/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/05/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/05/2019
FIMP
FINAL DISPOSITION PROCESSED
30/04/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/04/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
15/01/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/10/2018
PUBO
PUBLISHED FOR OPPOSITION
30/10/2018
GPNX
NOTIFICATION PROCESSED BY IB
26/10/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/10/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/10/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/10/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/09/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
18/09/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/09/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
18/09/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/09/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/08/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/08/2018
ALIE
ASSIGNED TO LIE
30/08/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/08/2018
RFNT
REFUSAL PROCESSED BY IB
09/03/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/02/2018
RFRR
REFUSAL PROCESSED BY MPU
16/02/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/02/2018
CNRT
NON-FINAL ACTION WRITTEN
12/02/2018
DOCK
ASSIGNED TO EXAMINER
06/02/2018
MAFR
APPLICATION FILING RECEIPT MAILED
29/11/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/11/2017
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
16/11/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VACSAF ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.